Last reviewed · How we verify

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. — Portfolio Competitive Intelligence Brief

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
VDCLD regimen VDCLD regimen phase 3 chemotherapy regimen Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AIO-Studien-gGmbH · 1 shared drug class
  2. Canadian Cancer Trials Group · 1 shared drug class
  3. Centre Georges Francois Leclerc · 1 shared drug class
  4. French Innovative Leukemia Organisation · 1 shared drug class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. National Research Center for Hematology, Russia · 1 shared drug class
  8. Ospedale Santa Croce-Carle Cuneo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.:

Cite this brief

Drug Landscape (2026). Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/changzhou-jinyuan-pharmaceutical-manufacturing-co-ltd. Accessed 2026-05-16.

Related